Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 35Sarcoma 34Thoracic 11Gynecologic 11Gastrointestinal 8Breast 8Endocrine 7Head & Neck 6CNS 5Dermatologic 4NET 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Neuroendocrine Tumors 3

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × pazopanib × NET × Clear all
NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
44 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT01099540 2015-12-29

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Samsung Medical Center

Phase 2 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡